ESR1 and breast carcinoma: Our finding that the expression of PAPP-A is a predictor of poor survival and early recurrence in breast cancer patients is consistent with previous reports demonstrating PAPP-A positive immunostaining as a predictor of early recurrence in patients with stage II breast cancer or stage I estrogen receptor negative breast cancer23,24.